Key result
β-blockers show divergent signaling and extra-cardiac effects that influence clinical outcomes in heart failure.
Why the study?
Although beta-blockers are a cornerstone in cardiovascular disease, their effectiveness for certain indications and side effects remain debated, with only four of up to 20 licensed compounds used for heart failure therapy.
This review provides mechanistic insights into the diverse receptor-level and extra-cardiac effects of beta-blockers that influence their clinical efficacy in heart failure.
Answers are grounded in this paper and cite their sources.
Suggests potential for tailored β-blocker selection in HF with comorbidities; extends mechanistic insights but leaves clinical impact open to prospective trials.
β-blockers are a solid pillar in the treatment of cardiovascular diseases. However, they are highly discussed regarding effectiveness for certain indications and side-effects. Even though there are up to 20 licensed compounds, only four are used for heart failure (HF) therapy. On the receptor level several key characteristics seem to influence the clinical outcome: subtype selectivity, antagonistic vs (inverse/biased) agonistic properties and -in particular- ancillary capacities. On a molecular level, divergent and novel signaling patterns are being identified and extra-cardiac effects on e.g. inflammation, metabolism and oxidative stress are highlighted. This review discusses different well-known and newly discovered characteristics that need to be considered for HF therapy and in the context of co-morbidities.
No takes yet. Share an insight, caveat, or question.
Brand et al. (2024) conducted a review in Heart failure and cardiovascular diseases. β-blockers was evaluated. β-blockers exhibit divergent signaling patterns and extra-cardiac effects on inflammation, metabolism, and oxidative stress that influence clinical outcomes in heart failure therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: